Brainsway (NASDAQ:BWAY) Lowered to “Hold” Rating by Wall Street Zen

Brainsway (NASDAQ:BWAY) was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

Separately, HC Wainwright reissued a “buy” rating and issued a $16.00 price objective on shares of Brainsway in a research note on Monday, June 9th.

Brainsway Stock Down 0.6%

Shares of NASDAQ:BWAY opened at $11.76 on Friday. Brainsway has a 52 week low of $6.65 and a 52 week high of $13.65. The stock has a market capitalization of $222.26 million, a P/E ratio of 58.80 and a beta of 1.42. The firm has a fifty day simple moving average of $11.85 and a two-hundred day simple moving average of $10.47.

Brainsway (NASDAQ:BWAY) last issued its quarterly earnings data on Tuesday, May 13th. The company reported $0.04 EPS for the quarter, topping analysts’ consensus estimates of $0.02 by $0.02. Brainsway had a net margin of 9.01% and a return on equity of 7.35%. The business had revenue of $11.54 million during the quarter, compared to analysts’ expectations of $11.45 million. On average, analysts expect that Brainsway will post 0.08 earnings per share for the current year.

Hedge Funds Weigh In On Brainsway

A number of large investors have recently made changes to their positions in the company. Two Sigma Investments LP boosted its stake in shares of Brainsway by 2.0% during the 4th quarter. Two Sigma Investments LP now owns 92,755 shares of the company’s stock worth $875,000 after purchasing an additional 1,786 shares during the period. Cubist Systematic Strategies LLC boosted its stake in shares of Brainsway by 14.6% during the 4th quarter. Cubist Systematic Strategies LLC now owns 19,228 shares of the company’s stock worth $181,000 after purchasing an additional 2,446 shares during the period. Huntleigh Advisors Inc. boosted its stake in shares of Brainsway by 5.7% during the 2nd quarter. Huntleigh Advisors Inc. now owns 77,416 shares of the company’s stock worth $1,018,000 after purchasing an additional 4,143 shares during the period. Lazard Asset Management LLC purchased a new position in shares of Brainsway during the 4th quarter worth about $44,000. Finally, NewEdge Advisors LLC boosted its stake in shares of Brainsway by 61.5% during the 1st quarter. NewEdge Advisors LLC now owns 19,828 shares of the company’s stock worth $188,000 after purchasing an additional 7,549 shares during the period. 30.11% of the stock is owned by hedge funds and other institutional investors.

Brainsway Company Profile

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.